Source: PharmiWeb

HistoGeneX: BluePrint Phase 2 Demonstrates Digital Pathology Review Equivalent to Glass Slides

BluePrint Phase 2 Demonstrates Digital Pathology Review Equivalent to Glass SlidesYOKOHAMA, Japan, Oct.

Read full article »
HistoGeneX's Competitors | HistoGeneX's News | HistoGeneX's Financials
Stay up-to-date with the latest news on HistoGeneX
Est. Annual Revenue
$25-100M
Est. Employees
100-250
Mark Kockx's photo - CEO of HistoGeneX

CEO

Mark Kockx

CEO Approval Rating

68/100

Read more
Stay up-to-date with the latest news on HistoGeneX